de la Torre R, Yubero-Lahoz S, Pardo-Lozano R, Farre M (2012) MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? Front Genet 3:235

PubMed  PubMed Central  Google Scholar 

Howes OD, Shatalina E (2022) Integrating the neurodevelopmental and dopamine hypotheses of schizophrenia and the role of cortical excitation-inhibition balance. Biol Psychiatry 92:501–513

Article  PubMed  Google Scholar 

Huang M, Panos JJ, Kwon S, Oyamada Y, Rajagopal L, Meltzer HY (2014) Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism. J Neurochem 128:938–949

Article  CAS  PubMed  Google Scholar 

Ichikawa J, Kuroki T, Kitchen MT, Meltzer HY (1995) R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. Eur J Pharmacol 287:179–184

Article  CAS  PubMed  Google Scholar 

Kuribara H (1994) Effects of SUN 8399, a potent and selective 5-HT1A agonist, on conflict behavior and ambulatory activity in mice: comparison with those of buspirone, tandospirone and diazepam. Jpn J Pharmacol 64:273–280

Article  CAS  PubMed  Google Scholar 

Kuroki T, Ichikawa J, Dai J, Meltzer HY (1996) R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex. Brain Res 743:357–361

Article  CAS  PubMed  Google Scholar 

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41

Article  CAS  PubMed  Google Scholar 

Lewis DA, Curley AA, Glausier JR, Volk DW (2012) Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci 35:57–67

Article  CAS  PubMed  Google Scholar 

Leza JC, Garcia-Bueno B, Bioque M, Arango C, Parellada M, Do K, O’Donnell P, Bernardo M (2015) Inflammation in schizophrenia: a question of balance. Neurosci Biobehav Rev 55:612–626

Article  PubMed  Google Scholar 

Liu Y, Ouyang P, Zheng Y, Mi L, Zhao J, Ning Y, Guo W (2021) A selective review of the excitatory-inhibitory imbalance in schizophrenia: underlying biology, genetics, microcircuits, and symptoms. Front Cell Dev Biol 9:664535

Article  PubMed  PubMed Central  Google Scholar 

Miller DK, Oelrichs CE, Sun GY, Simonyi A (2014) Subchronic apocynin treatment attenuates methamphetamine-induced dopamine release and hyperactivity in rats. Life Sci 98:6–11

Article  CAS  PubMed  Google Scholar 

Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic Press, Sydney

Rasmusson AM, Goldstein LE, Deutch AY, Bunney BS, Roth RH (1994) 5-HT1a agonist +/-8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine. Synapse 18:218–224

Article  CAS  PubMed  Google Scholar 

Rogoz Z, Skuza G (2011) Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats. Pharmacol Rep 63:1547–1552

Article  CAS  PubMed  Google Scholar 

Sills TL, Greenshaw AJ, Baker GB, Fletcher PJ (1999a) Acute fluoxetine treatment potentiates amphetamine hyperactivity and amphetamine-induced nucleus accumbens dopamine release: possible pharmacokinetic interaction. Psychopharmacology 141:421–427

Article  CAS  PubMed  Google Scholar 

Sills TL, Greenshaw AJ, Baker GB, Fletcher PJ (1999b) The potentiating effect of sertraline and fluoxetine on amphetamine-induced locomotor activity is not mediated by serotonin. Psychopharmacology 143:426–432

Article  CAS  PubMed  Google Scholar 

Steullet P, Cabungcal JH, Monin A, Dwir D, O’Donnell P, Cuenod M, Do KQ (2016) Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a central hub in schizophrenia pathophysiology? Schizophr Res 176:41–51

Article  CAS  PubMed  Google Scholar 

Steullet P, Cabungcal JH, Coyle J, Didriksen M, Gill K, Grace AA, Hensch TK, LaMantia AS, Lindemann L, Maynard TM, Meyer U, Morishita H, O’Donnell P, Puhl M, Cuenod M, Do KQ (2017) Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. Mol Psychiatry 22:936–943

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun T, Hu G, Li M (2009) Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs. Eur J Pharmacol 602:334–342

Article  CAS  PubMed  Google Scholar 

Tomkins DM, Otton SV, Joharchi N, Berns T, Wu D, Corrigall WA, Sellers EM (1997) Effect of CYP2D1 inhibition on the behavioural effects of d-amphetamine. Behav Pharmacol 8:223–235

CAS  PubMed  Google Scholar 

Tsugawa S, Noda Y, Tarumi R, Mimura Y, Yoshida K, Iwata Y, Elsalhy M, Kuromiya M, Kurose S, Masuda F, Morita S, Ogyu K, Plitman E, Wada M, Miyazaki T, Graff-Guerrero A, Mimura M, Nakajima S (2019) Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: a systematic review and meta-analysis. J Psychopharmacol 33:1199–1214

Article  CAS  PubMed  Google Scholar 

Uehara T, Sumiyoshi T, Matsuoka T, Itoh H, Kurachi M (2007) Effect of prefrontal cortex inactivation on behavioral and neurochemical abnormalities in rats with excitotoxic lesions of the entorhinal cortex. Synapse 61:391–400

Article  CAS  PubMed  Google Scholar 

Uehara T, Sumiyoshi T, Seo T, Itoh H, Matsuoka T, Suzuki M, Kurachi M (2009) Long-term effects of neonatal MK-801 treatment on prepulse inhibition in young adult rats. Psychopharmacology 206:623–630

Article  CAS  PubMed  Google Scholar 

Uehara T, Sumiyoshi T, Seo T, Matsuoka T, Itoh H, Suzuki M, Kurachi M (2010) Neonatal exposure to MK-801, an N-methyl-d-aspartate receptor antagonist, enhances methamphetamine-induced locomotion and disrupts sensorimotor gating in pre- and postpubertal rats. Brain Res 1352:223–230

Article  CAS  PubMed  Google Scholar 

Uehara T, Sumiyoshi T, Seo T, Matsuoka T, Itoh H, Kurachi M (2012) T-817MA, but not haloperidol and risperidone, restores parvalbumin-positive gamma -aminobutyric acid neurons in the prefrontal cortex and hippocampus of rats transiently exposed to MK-801 at the neonatal period. ISRN Psychiatry 2012:947149

Article  PubMed  PubMed Central  Google Scholar 

Uehara T, Kurachi M, Kondo T, Abe H, Zhao QL, Itoh H, Sumiyoshi T, Suzuki M (2021) Apocynin-tandospirone derivatives demonstrate antioxidant properties in the animal model of schizophrenia. Advances in Redox Research. https://doi.org/10.1016/j.arres.2021.100013

Article  Google Scholar 

Uehara T, Kurachi M, Kondo T, Abe H, Itoh H, Sumiyoshi T, Suzuki M (2022) Apocynin-Tandospirone Derivatives Suppress Methamphetamine-Induced Hyperlocomotion in Rats with Neonatal Exposure to Dizocilpine. J Pers Med 12

Welter J, Meyer MR, Wolf EU, Weinmann W, Kavanagh P, Maurer HH (2013) 2-methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques. Anal Bioanal Chem 405:3125–3135

Article  CAS  PubMed  Google Scholar 

Yoshino T, Nisijima K, Katoh S, Yui K, Nakamura M (2002) Tandospirone potentiates thefluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the ratmedial frontal cortex. Neurochem Int 40:355–360

Article  Google Scholar